Journals / Turkish Journal of Gastroenterology / 2012 / Cilt: 23 - Sayı: 5

İntestinal infhamasyonun bir belirteci olarak fekal kalprotektin'in ülseratif kolitli hastalardaki değeri

The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis

Pages
509–514
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Fecal calprotectin is a useful marker in the diagnosis of active disease and evaluation of clinical and endoscopic activity in ulcerative colitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: To assess intestinal inflammation, simple, inexpensive and objective tools are desirable in inflammatory bowel disease.
📊
Key Findings & Data:Materials and Methods: Sixty patients with a diagnosis of ulcerative colitis and 20 controls were recruited into the study.
💡
Conclusion & Impact:Conclusions: Fecal calprotectin is a useful marker in the diagnosis of active disease and evaluation of clinical and endoscopic activity in ulcerative colitis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: To assess intestinal inflammation, simple, inexpensive and objective tools are desirable in inflammatory bowel disease. This study aimed to evaluate fecal calprotectin as a marker of active disease in ulcerative colitis. Materials and Methods: Sixty patients with a diagnosis of ulcerative colitis and 20 controls were recruited into the study. The disease activity of ulcerative colitis was determined by modified Truelove-Witts criteria and Rachmilewitz endoscopic index. The enzyme-linked immunosorbent assay was used to measure the concentrations of fecal calprotectin. C-reactive protein, erythrocyte sedimentation rate and hemogram were also measured, and inflammatory markers were compared with fecal calprotectin in determining disease activity. Results: Fecal calprotectin concentration in the patients with active ulcerative colitis (n=30) was significantly higher than that in the inactive ulcerative colitis group (n=30) and in the controls (n=20) (95% confidence interval: 232.5 (0.75-625) vs 11.7 (0.2-625), 7.5 (0.5-512) mg/L, p<0.001). There was no significant difference between the patients with inactive ulcerative colitis and controls (p>0.05). The calprotectin concentration was greater in the patients with a more severe clinical index, higher endoscopic activity (>4), elevated C-reactive protein, leukocytosis, and extensive colitis (p<0.05). The areas under the curve of the receiver operating characteristics were 0.817, 0.809, 0.532, and 0.507 for C-reactive protein, fecal calprotectin, leukocyte count, and erythrocyte sedimentation rate, respectively. There was a significant correlation between the fecal calprotectin concentration and the endoscopic activity in ulcerative colitis (r = 0.548, p<0.001). Conclusions: Fecal calprotectin is a useful marker in the diagnosis of active disease and evaluation of clinical and endoscopic activity in ulcerative colitis.

Özet

Amaç: nşamatuvar barsak hastalığında, intestinal inşamasyonun basit, ucuz ve objektif yollarla saptanması istenen bir durumdur. Bu çalışmanın amacı ülseratif kolitte aktif hastalık belirteci olarak fekal kalprotektin düzeylerini değerlendirmektir. Gereç ve Yöntem: Çalışmaya 60 ülseratif kolitli hasta ve 20 sağlıklı kontrol dahil edildi. Ülseratif kolit hastalık aktivitesi modifiye Truelove- Witts kriteri ve Rachmilewitz endoskopik indeksine göre ölçüldü. Fekal kalprotektin konsantrasyonu ölüçümünde EL SA yöntemi kullanıldı. C-reaktif protein, eritrosit sedimantasyon hızı ve hemogram ölçümleri de yapıldı ve hastalık aktivitesinin saptanması açısından fekal kalprotektin ile bu inşamatuvar belirteçler karşılaştırıldı. Bulgular: Aktif ülseratif kolitli hastalarda (n=30) saptanan fekal kalprotektin konsantrasyonu, inaktif ülseratif kolitli hastalar (n=30) ve kontrol grubuna (n=20) göre anlamlı oranda yüksekti (%95 güven aralığında sırasıyla; 232.5 (0.75-625), 11.7 (0.2-625) ve 7.5 (0.5-512) mg/L, P 0.05). Kalprotektin konsantrasyonu, daha ciddi klinik indeksi, yüksek endoskopik aktivitesi (>4), artmış C-reaktif proteini, lökositozu ve ekstensif koliti olan hastalarda daha yüksekti (P < 0.05). Eğ- ri altındaki alan, C-reaktif protein, fekal kalprotektin, lökosit sayımı ve eritrosit sedimantasyon hızı için sırasıyla 0.817, 0.809, 0.532 ve 0.507 olarak bulundu. Fekal kalprotektin konsantrasyonu ile endoskopik aktivite arasında anlamlı ilişki saptandı (r = 0.548, P < 0.001). Sonuç: Fekal kalprotektin, ülseratif kolitli hastalarda aktif hastalık tanısı ve klinik ve endoskopik aktivitenin değerlendirilmesinde yararlı bir belirteçtir.

🔖

Cite This Article

ÖNAL, İ. K., BEYAZIT, Y., ŞENER, B., SAVUK, B., ÖZER, D. E., SAYILIR, A., ÖZTAŞ, E., TORUN, S., ÖZDERİN, Y. Ö., TUNÇ, B. D., ÜLKER, A., DAĞLI, Ü. (2012). İntestinal infhamasyonun bir belirteci olarak fekal kalprotektin'in ülseratif kolitli hastalardaki değeri. Turkish Journal of Gastroenterology, Cilt: 23 - Sayı: 5, 509–514. https://ajindex.com/articles/409691

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipationand diarrhoeapredominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14: 409-12
  2. Dunker MS, Ten Hove T, Bemelman WA, et al. Interleukin-6, C-reactive protein, and expression of human leukocyte antigen-DR on peripheral blood mononuclear cells in patients after laparoscopic vs conventional bowel resection: a randomized study. Dis Colon Rectum 2003; 46: 1238-44
  3. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflammtory Bowel Dis 2004; 10: 661-5
  4. Sachar DB, Smith H, Chan S, et al. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986; 8: 651-4
  5. Lubega J, Davies TJ. A comparison of serum mucoprotein with serum alpha 2 acid glycoprotein, haptoglobin, and alpha 1 antitrypsin assays in monitoring inflammatory bowel disease. Clin Chim Acta 1990; 188: 59-69. 6. van Wersch JW, Houben P, Rijken J. Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 1990; 28: 513-7
  6. Larsen TB, Nielsen JN, Fredholm L, et al. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 2002; 32: 92-6
  7. Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111granulocyte excretion. Gastroenterology 1986; 90: 1121-8
  8. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 113-23
  9. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-8
  10. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 1085-91
  11. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-80
  12. Costa F, Mumolo MG, Bellini M, et al. Role of fa